Rockwell Medical (NASDAQ:RMTI) issued its quarterly earnings data on Thursday. The company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.04), MarketWatch Earnings reports. Rockwell Medical had a negative return on equity of 117.31% and a negative net margin of 53.40%.

NASDAQ:RMTI opened at $5.03 on Friday. The firm has a market cap of $289.45 million, a P/E ratio of -9.86 and a beta of 2.09. Rockwell Medical has a one year low of $2.19 and a one year high of $6.92.

A number of analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Rockwell Medical from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research note on Thursday, November 15th. ValuEngine cut shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research note on Friday, March 1st.

A number of large investors have recently added to or reduced their stakes in RMTI. BlackRock Inc. raised its stake in Rockwell Medical by 0.8% during the 3rd quarter. BlackRock Inc. now owns 3,221,245 shares of the company’s stock valued at $13,593,000 after purchasing an additional 25,322 shares during the last quarter. Virtu Financial LLC raised its stake in Rockwell Medical by 202.3% during the 3rd quarter. Virtu Financial LLC now owns 36,050 shares of the company’s stock valued at $152,000 after purchasing an additional 24,124 shares during the last quarter. Bridgeway Capital Management Inc. raised its stake in Rockwell Medical by 160.6% during the 3rd quarter. Bridgeway Capital Management Inc. now owns 91,200 shares of the company’s stock valued at $385,000 after purchasing an additional 56,200 shares during the last quarter. Jefferies Group LLC acquired a new position in Rockwell Medical during the 3rd quarter valued at $120,000. Finally, Rehmann Capital Advisory Group raised its stake in Rockwell Medical by 27.5% during the 3rd quarter. Rehmann Capital Advisory Group now owns 60,192 shares of the company’s stock valued at $254,000 after purchasing an additional 12,980 shares during the last quarter. Hedge funds and other institutional investors own 19.02% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2019/03/15/rockwell-medical-rmti-releases-earnings-results-misses-expectations-by-0-04-eps.html.

Rockwell Medical Company Profile

Rockwell Medical, Inc operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment.

See Also: What are the benefits of momentum investing?

Earnings History for Rockwell Medical (NASDAQ:RMTI)

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.